Halozyme competitors

Zippia score 4.8

Halozyme main competitors are Gilead Sciences, Genentech, and Alder Biopharmaceuticals.

Competitor Summary. See how Halozyme compares to its main competitors:

Amgen has the most employees (22,000).
Employees at Gilead Sciences earn more than most of the competitors, with an average yearly salary of $99,828.
The oldest company is Genentech, founded in 1976.

Work at Halozyme?

Share your experience

Halozyme vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Halozyme	1998	4.8	San Diego, CA	1	$1.0B	136
Regeneron	1988	4.9	Tarrytown, NY	7	$14.2B	9,123
Geron	1990	4.6	Menlo Park, CA	3	$77.0M	15
Genentech	1976	4.5	South San Francisco, CA	5	$166.9M	13,638
Amgen	1980	4.8	Thousand Oaks, CA	9	$33.4B	22,000
Gilead Sciences	1987	4.5	Foster City, CA	9	$28.8B	11,800
Cornerstone Pharmaceuticals	2000	3.4	New York, NY	1	$890,000	30
La Jolla Pharmaceutical	1989	4.1	San Diego, CA	1	$75.7M	169
Vical	1987	3.5	San Diego, CA	1	$12.4M	213
Protea Biosciences Group	2001	3.4	Morgantown, WV	1	$2.4M	35
DermTech	1996	3.9	San Diego, CA	1	$15.3M	114
CyLex	1994	3.7	Columbia, MD	1	$3.1M	200
Alder Biopharmaceuticals	2004	4.4	Bothell, WA	2	$6.5M	202

Rate Halozyme's competitiveness in the market.

Halozyme salaries vs competitors

Among Halozyme competitors, employees at Gilead Sciences earn the most with an average yearly salary of $99,828.

Compare Halozyme salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Halozyme	$93,996	$45.19	-
Regeneron	$85,589	$41.15	-
Geron	$56,851	$27.33	-
Genentech	$97,473	$46.86	-
Amgen	$93,349	$44.88	-
Gilead Sciences	$99,828	$47.99	-

Compare Halozyme job title salaries vs competitors

Company	Highest salary	Hourly salary
Halozyme	$44,715	$21.50
Gilead Sciences	$47,443	$22.81
Amgen	$47,435	$22.81
Regeneron	$46,397	$22.31
Geron	$43,951	$21.13
Genentech	$42,921	$20.64
CyLex	$42,456	$20.41
Alder Biopharmaceuticals	$40,975	$19.70
Protea Biosciences Group	$39,339	$18.91
La Jolla Pharmaceutical	$39,201	$18.85
Vical	$36,741	$17.66
Cornerstone Pharmaceuticals	$35,546	$17.09
DermTech	$34,672	$16.67

Do you work at Halozyme?

Is Halozyme able to compete effectively with similar companies?

Halozyme jobs

Halozyme demographics vs competitors

Compare gender at Halozyme vs competitors

Job title	Male	Female
Geron	44%	56%
Regeneron	54%	46%
Gilead Sciences	56%	44%
Amgen	57%	43%
La Jolla Pharmaceutical	65%	35%
Halozyme	-	-

Male

Female

100%

75%

50%

25%

Halozyme

La Jolla Pharmaceutical

Amgen

Gilead Sciences

Regeneron

Geron

25%

50%

75%

100%

Compare race at Halozyme vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Amgen	49%	24%	7%	15%	5%	9.7
Geron	46%	20%	7%	22%	4%	9.2
Gilead Sciences	44%	20%	8%	23%	6%	9.8
La Jolla Pharmaceutical	55%	22%	9%	7%	8%	6.8
Regeneron	54%	15%	10%	17%	4%	9.8
Genentech	45%	20%	7%	22%	6%	9.8

Halozyme revenue vs competitors

Halozyme revenue is $1.0B. Among it's competitors, the company with the highest revenue is Amgen, $33.4B . The company with the lowest revenue is Cornerstone Pharmaceuticals, $890.0K.

Halozyme and similar companies CEOs

CEOBio

Paul Cleveland

Alder Biopharmaceuticals

Robert A. Bradway

Amgen

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

John A. Scarlett M.d

Geron

John 'Chip' Scarlett is a Co-Founder at Covance and Board Member at CYTOMX THERAPEUTICS, INC. and is based in Menlo Park, California. He has worked as Board Member at GERON CORP, Board Member at Chiasma Inc, and Adjunct Assistant Professor of Medicine at Hospital of the University of Pennsylvania. John works or has worked as Various Positions at Mcneil Pharmaceuticals and Dir:Medical Research & Svcs at Mcneil Pharmaceuticals. He studied at University of Colorado Boulder between 1980 and 1982, University of Chicago - The Pritzker School of Medicine between 1973 and 1977, and Earlham College between 1969 and 1973.

Daniel O’Day

Gilead Sciences

Vijay Samant

Vical

Vijay Samant is a Board Member at Brickell Biotech Inc. He has worked as President/CEO at Vical; Trustee at International Vaccine Institute (IVI); and VP:Vaccine/Exec Dir:Materials Mgmt at MERCK & CO., INC.. Vijay studied at Columbia University, University of Mumbai, and MIT Sloan.

Alexander Hardy

Genentech

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Brad L Stewart

CyLex

Stephen Turner

Protea Biosciences Group

Stephen Turner is Chief Executive Officer and Chairman of the Board, positions he has held since founding the company in July, 2001. From 1999 to 2001 he served as President and CEO of Quorum Sciences, Inc. From 1984 to 1997 he was President and CEO of Oncor, Inc. He founded Bethesda Research Laboratories, Inc. in 1975 and served as its Chairman and CEO from 1975 to 1983, at which time BRL became the molecular biology division of Life Technologies, Inc. Prior to commencing his career in biotechnology, Mr. Turner held the position of Director of Marketing for the Clinical Microbiology Division of Becton, Dickinson & Co. He received his B.A. from Stanford University in 1967. In 1994 he received the Ernst & Young Entrepreneur of the Year Award in Life Sciences for the Washington D.C. Region.